Accéder au contenu
Merck

MIAT inhibits proliferation of cervical cancer cells through regulating miR-150-5p.

Cancer cell international (2020-06-19)
Yanbin Liu, Xingzhi Li, Hui Zhang, Yali Huang
RÉSUMÉ

To characterize the MIAT expression in cervical cancer and elucidate its mechanistic involvement in the tumor biology of this disease. The relative expression of MIAT and miR-150 was determined by real-time PCR. Cell proliferation was measured by the CCK-8 and clonogenic assay. The anchorage-independent growth was evaluated by soft agar assay. The in vivo tumor progression was assayed with xenograft mice model. The regulatory effect of miR-150 on MIAT was interrogated by luciferase reporter assay. The endogenous CNKD1B protein was detected by western blotting. The low expression of MIAT was characterized in cervical cancer, which associated with relatively poor prognosis. Ectopic expression of MIAT inhibited malignant growth of cervical cancer both in vitro and in vivo. Mechanistically, MIAT regulated CDKN1B expression via competition with miR-150, and miR-150-inhibition directly suppressed cervical cancer cell growth. Our study characterized the anti-tumor property of MIAT in cervical cancer and elucidated its competitively regulation of CDKN1B with miR-150. Our data highlighted the critical role of MIAT-miR-150-CDKN1B signaling axis in cervical cancer.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-beta-Actin antibody, Rabbit monoclonal, clone SP124, recombinant, expressed in proprietary host, affinity isolated antibody
Sigma-Aldrich
Anti-CDKN1B antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody